International Circulation:   Do you think there is more on the horizon than there was in the past?
　Dr. Antman: I think we are also seeing some interesting evolution of the methodology by which we deliver this information. For example， the pre-recorded case theater will be revealed this year. We are also making great use of all the digital enhancements in this digital era. One can get a copy of the program book as an iBook for the iPad or iPhone. You can download it as a searchable database directly onto your iPhone. It is possible to search that database by a number of different filters: by topic， by day， by speaker， and combinations of those filters. If you search the website scientificsessions.org， you will see links on the left hand side that will allow you to download all the digital forms of the program.

　　国际循环：你认为与过去相比我们是否有更高的起点?

　　Elliot Antman教授：我认为通过的信息的传递，我们在方法上也看到了一些有趣的进展。例如，将今年展示的预录的案例现场。我们也在最大程度的使个数字时代的数字功能发挥大极致。你可以通过iPad或iPhone得到一份作为iBook的计划书。您可以把它作为一个可搜索的数据库直接下载到你的iPhone。你也可以通过几种不同的关键词在数据库进行搜索: 通过主题，日期，作者，并且可以组合这些关键词进行联合搜索。如果你搜索网站scientificsessions.org，您将看到左边的链接，这将允许您下载所有的数字形式的应用程序。

　　 International Circulation:   There has been some fear that the drug pipeline is slowing down， if not drying up. What are you comments on this?
　 Dr. Antman: You are correct in one sense in that Big Pharma has a pipeline that is drying up. However， there are very interesting smaller biotechnology companies that are producing therapeutics. Those smaller biotech companies are the source of the materials that I have just alluded to: new drugs for managing diabetes， hypercholesterolemia， or heart failure. Often， these new biotech companies ultimately merge with larger pharma company. The answer to your question is a complicated one. Big Pharma probably is having some of their pipeline dry up， but the emerging biotech companies are producing some very interesting therapeutic products that we are bringing to the meeting for presentation and scientific discussion of their pros and cons.

　　国际循环：已经有一些人担心，药物管道如果不是正在干涸就是正在放缓。您对此有什么看法?

　　Elliot Antman教授：在 某种意义上你是正确的，大型制药公司所拥有的新药开发制作管道正在枯竭。然而，有很多令人关注的小型生物技术公司正在生产新的药物和疗法。那些规模较小的生物技术公司正是我刚刚提到的: 治疗糖尿病、高胆固醇血症、或心脏衰竭新药物材料的源头。通常，这些新的生物技术公司最终都会与更大的制药公司合并。你所问问题的答案很复杂。大型制药公司可能有一些药物制作管道正在枯竭，但新兴生物技术公司正在生产一些非常有趣的治疗产品，我们将在会议上对这些产品进行介绍，并系统地讨论他们本身的优点和缺点。

　　 International Circulation:   Would you call this a democratization of the drug making process?
　 Dr. Antman: I think that is an interesting observation. Yes.

　　国际循环：你会把这称为民主化的药物制作过程吗?

　　Elliot Antman教授：是的，我认为看到这样的过程是十分有趣的。